Cargando…

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323440/ https://www.ncbi.nlm.nih.gov/pubmed/22390313 http://dx.doi.org/10.1186/1756-8722-5-4

Ejemplares similares

A case of mistaken identity: When lupus masquerades as primary myelofibrosis
por: Hasrouni, Edy, et al.
Publicado: (2013)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
por: Negoro, Eiju, et al.
Publicado: (2016)

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
por: Traina, Fabiola, et al.
Publicado: (2012)

SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD
por: Gondek, Lukasz P., et al.
Publicado: (2007)

Molecular Pathogenesis of Myelodysplastic Syndromes
por: Visconte, Valeria, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
por: Visconte, Valeria, et al.
Publicado: (2016)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
por: Visconte, Valeria, et al.
Publicado: (2015)

Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
por: Guan, Yihong, et al.
Publicado: (2020)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
por: Visconte, Valeria, et al.
Publicado: (2014)

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Recurrent genetic defects on chromosome 5q in myeloid neoplasms
por: Hosono, Naoko, et al.
Publicado: (2016)

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
por: Negrotto, Soledad, et al.
Publicado: (2011)

TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p
por: Jasek, Monika, et al.
Publicado: (2009)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
por: Yang, Lili, et al.
Publicado: (2012)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Somatic SETBP1 mutations in myeloid malignancies
por: Makishima, Hideki, et al.
Publicado: (2013)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
por: Cluzeau, Thomas, et al.
Publicado: (2017)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Metaphase cytogenetics and single nucleotide polymorphism arrays in myeloid malignancies()
por: da Silva, Fernanda Borges, et al.
Publicado: (2015)

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
por: Jana, Bagi, et al.
Publicado: (2014)

Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease
por: Visconte, Valeria, et al.
Publicado: (2014)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

New approaches to idiopathic neutropenia in the era of clonal hematopoiesis
por: Ogbue, Olisaemeka D., et al.
Publicado: (2023)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dubd4ag0krlv5ou9a0ke3pm2fj